| Market Cap | 1.97M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -39.02M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -80.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -90.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 0.23 | Shares Outstanding | 423.36M | 52W Low Chg | 143.00% |
| Insider Own | 0.99% | ROA | -38.52% | Shares Float | 418.75M | Beta | 1.98 |
| Inst Own | - | ROE | -315.85% | Shares Shorted/Prior | -/- | Price | 0.00170 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 253,032 | Target Price | - |
| Oper. Margin | - | Earnings Date | Oct 16 | Volume | 422,167 | Change | -37.04% |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
